| Patent Number |
Title Of Patent |
Date Issued |
| D530817 |
Syringe tool |
October 24, 2006 |
|
| D530009 |
Syringe tool |
October 10, 2006 |
|
| D450835 |
Needle-less hypodermic jet injection apparatus |
November 20, 2001 |
|
| D339869 |
Vial container |
September 28, 1993 |
|
| D332397 |
Vial shipping container |
January 12, 1993 |
|
| 7626033 |
Compounds for the modulation of PPAR.gamma. activity |
December 1, 2009 |
| Modulators of PPAR.gamma. activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity. |
| 7626030 |
Compounds and methods of use |
December 1, 2009 |
| Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment |
| 7619066 |
IL-1ra variants |
November 17, 2009 |
| The present invention provides for an IL-1ra having reduced aggregation, methods of reducing aggregation of IL-1ra, and kits comprising an IL-1ra having reduced aggregation. |
| 7612060 |
Triazoles and methods of use |
November 3, 2009 |
| Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and t |
| 7611865 |
Polynucleotides encoding truncated glial cell line-derived neurotrophic factor |
November 3, 2009 |
| Disclosed are novel proteins, referred to as truncated glial cell line-derived neurotrophic factor (truncated GDNF) proteins, that promote dopamine uptake by dopaminergic cells and promote the survival of nerve cells. Also disclosed are processes for obtaining the truncated GDNF prot |
| 7611857 |
IL-receptor like molecules and uses thereof |
November 3, 2009 |
| The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides |
| 7605289 |
Benzamide derivatives and uses related thereto |
October 20, 2009 |
| Benzamide derivatives of formula I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particularly in the treatment of diabetes, obesity, and relate |
| 7605261 |
Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositio |
October 20, 2009 |
| The invention relates to new products of formula (I): ##STR00001## in which: Y represents oxygen or sulphur, Z represents C.dbd.CH2, CH--CH3 or CH2, R1 represents hydrogen, morpholinyl or the ##STR00002## radical. In which the two nitrogen atoms are linear or form a cyclic radical, X |
| 7605120 |
Antagonists of the brandykinin B1 receptor |
October 20, 2009 |
| The present invention relates to certain biologically active peptides and conjugated peptides which can be used as therapeutics or prophylactics against diseases or conditions linked to B1 as the causative agent. In a preferred embodiment of the invention biologically active PEG-conjugat |
| 7601841 |
Quinolinyl and benzothiazolyl modulators |
October 13, 2009 |
| Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR.gamma.. In particular, the compounds of the invention modulate the function of PPAR.gamma.. The subject methods are particularly useful in the t |
| 7601818 |
Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors |
October 13, 2009 |
| This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating |
| 7592429 |
Sclerostin-binding antibody |
September 22, 2009 |
| Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. |
| 7585500 |
Fully human monoclonal antibodies to IL-13 |
September 8, 2009 |
| The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences |
| 7582803 |
Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treatin |
September 1, 2009 |
| The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: ##STR00001## where the definitions of the variables Q, L.sup.1, ##STR00002## L.sup.2, M, X, L.sup.3, and A are provided herein. The |
| 7582761 |
Vanilloid receptor ligands and their use in treatments |
September 1, 2009 |
| Therapeutic benzimidazoles having the general structure: ##STR00001## and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, |
| 7582657 |
Vanilloid receptor ligands and their use in treatments |
September 1, 2009 |
| Compounds having the general structure ##STR00001## and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflam |
| 7582631 |
Substituted heterocyclic compounds and methods of use |
September 1, 2009 |
| The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, tr |
| 7582465 |
Beta secretase genes |
September 1, 2009 |
| Disclosed are novel genes encoding beta secretase polypeptides. Also disclosed are methods of making and using the polypeptides. |
| 7579347 |
Vanilloid receptor ligands and their use in treatments |
August 25, 2009 |
| Compounds having the general structure ##STR00001## and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflam |
| 7579316 |
Compositions and methods to modulate an immune response to an immunogenic therapeutic agent |
August 25, 2009 |
| Methods and compositions for modulating an immune response to an immunogenic therapeutic agent are disclosed. One of the disclosed methods comprises administering an effective amount of CTLA-4 to decrease the incidence of an immune reaction in conjunction with the administration of a |
| 7579180 |
Beta secretase polypeptides |
August 25, 2009 |
| Disclosed are novel genes encoding beta secretase polypeptides. Also disclosed are methods of making and using the polypeptides. |
| 7572934 |
Substituted biphenyl GPR40 modulators |
August 11, 2009 |
| The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: ##STR00001## where the definitions of the variables are provided herein. The present invention also provides compositions that include, |
| 7572783 |
Substituted benzofused heterocycles |
August 11, 2009 |
| The present invention relates to the compounds of Formula I, their preparation and pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful, for example, for the treatment and prevention of obesity, obesity-related disorders and eating dis |
| 7569726 |
Indanone derivatives that inhibit prolyl hydroxylase |
August 4, 2009 |
| Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure: ##STR00001## where the definitions of the variables are provided herein. |
| 7569387 |
Antibody to TNF receptor-like molecules |
August 4, 2009 |
| Novel MK61 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing MK61 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of dis |
| 7560551 |
Aurora kinase modulators and method of use |
July 14, 2009 |
| The present invention relates to chemical compounds having a general formula I ##STR00001## wherein A.sup.1, A.sup.2, C.sup.1, C.sup.2, D, L.sup.1, L.sup.2, Z and R.sup.1-8 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase recept |
| 7560460 |
Substituted piperazines and methods of use |
July 14, 2009 |
| Selected substituted piperazine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for pro |
| 7556623 |
Tool for use with a medication vial and/or a syringe |
July 7, 2009 |
| A tool for use with a medication vial and a syringe includes a housing having a top side, a bottom side, and a surrounding edge. A slotted aperture is defined in the housing and including a flange shaped to engage a vial cap. A cylindrical aperture is defined in the housing and sized |
| 7553848 |
Vanilloid receptor ligands and their use in treatments |
June 30, 2009 |
| bis-Bicyclic amides and derivatives thereof and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, a |
| 7553630 |
Methods for detecting metalloproteinase inhibitors |
June 30, 2009 |
| A novel metalloproteinase inhibitor, analogs thereof, polynucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders caused by excessive amounts of metalloproteinase are also disclosed. |
| 7544803 |
Vanilloid receptor ligands and their use in treatments |
June 9, 2009 |
| Compounds having the general structure ##STR00001## and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflam |
| 7544702 |
Bisaryl-sulfonamides |
June 9, 2009 |
| Bisaryl-sulfonamide compounds having the formula ##STR00001## wherein Ar, R.sup.1, R.sup.2, L, B, W, X, Y, and Z, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR.gamma. or PPAR.delta.. In particular, the |
| 7544519 |
Fhm a novel member of the TNF ligand supergene family: materials and methods for interaction mod |
June 9, 2009 |
| The present invention provides a purified polynucleotide encoding a novel polypeptide, designated Fhm, which belongs to the TNF gene superfamily; to purified Fhm polypeptide molecules; to antibodies that bind Fhm; to materials comprising such molecules; and to methods of using such m |
| 7541474 |
Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11.beta.-hydroxy steroid |
June 2, 2009 |
| The invention provides a process for preparing 11 .beta.-hydroxy steroid dehydrogenase type 1 inhibitors of formula 2 via a catalyzed reaction between a compound of formula 1 and a compound of formula R.sup.2LG in the presence of base: ##STR00001## where R.sup.1, R.sup.2, X, Y, and LG |
| 7541438 |
Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
June 2, 2009 |
| A human monoclonal antibody useful for the treatment of various diseases caused by human connective tissue growth factor (CTGF) and preventing the onset of the above diseases; medicinal uses thereof; and various monoclonal antibodies having various characteristics against various mam |
| 7541383 |
Asthma and allergic inflammation modulators |
June 2, 2009 |
| Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic di |
| 7538114 |
Glycine transporter-1 inhibitors |
May 26, 2009 |
| The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention de |
| 7534798 |
Vanilloid receptor ligands and their use in treatments |
May 19, 2009 |
| Compounds having the general structure ##STR00001## and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflam |
| 7531553 |
Heterocyclic compounds and methods of use |
May 12, 2009 |
| Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and |
| 7531321 |
Fibroblast growth factor-like molecules and uses thereof |
May 12, 2009 |
| The present invention provides Fibroblast Growth Factor-Like (FGF-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGF-L polypeptides. The invention further provides phar |
| 7528244 |
Regulators of apoptosis |
May 5, 2009 |
| The invention provides methods and compositions relating to apoptosis regulating proteins, known as Casper proteins, and related nucleic acids. The proteins may be produced recombinantly from transformed host cells from the disclosed Casper encoding nucleic acid or purified from human |
| 7524940 |
OB protein compositions and methods |
April 28, 2009 |
| The present invention provides methods and compositions for treating excess weight by administering OB protein in a form for constant supply, at a dosage of less than or equal to about 1 mg protein/kg body weight/day. Compositions and methods used for production of recombinant murine |
| 7524874 |
Vanilloid receptor ligands and their use in treatments |
April 28, 2009 |
| Compounds having the general structure ##STR00001## and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflam |
| 7524873 |
Calcium receptor modulating agents |
April 28, 2009 |
| The compounds of the invention are represented by the following general structure ##STR00001## or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including metho |
| 7524848 |
Diaza heterocyclic amide compounds and their uses |
April 28, 2009 |
| Diaza heterocyclic amide derivatives according to Formula (I) have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: ##STR00001## where R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, m, Q, X, and Y are set forth in |
